#
Cisplatin Intravenous
  • Drugs A to Z
  • Cisplatin (Intravenous)

Cisplatin (Intravenous)

Medically reviewed by Drugs.com. Last updated on Feb 27, 2022.

Intravenous route(Powder for Solution)

Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Consider dose reductions or alternative treatments in patients with renal impairment.Peripheral Neuropathy: cisplatin injection can cause dose-related peripheral neuropathy.Nausea and Vomiting: cisplatin injection can cause severe nausea and vomiting. Premedicate with antiemetics.Myelosuppression: cisplatin injection can cause severe myelosuppression with fatalities due to infections. Monitor blood counts and interrupt therapy accordingly .

Commonly used brand name(s)

In the U.S.

  • Platinol-AQ

Available Dosage Forms:

  • Powder for Solution
  • Solution

Therapeutic Class: Antineoplastic Agent

Pharmacologic Class: Platinum Coordination Complex

Uses for cisplatin

Cisplatin injection is used to treat advanced cancer of the bladder, ovaries, or testicles.

Cisplatin is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.

Cisplatin is to be given only by or under the direct supervision of a doctor.

Before using cisplatin

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For cisplatin, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to cisplatin or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of cisplatin injection in the pediatric population. Safety and efficacy have not been established. Cisplatin may increase the risk for serious ear or hearing problems in children younger that 5 years of age.

Geriatric

Appropriate st..